2500.Hk
2500.HK operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.
Business. 2500.HK operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
2500.HK operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.04, indicating a conservative leverage position. Its liquidity position is strong, with a current ratio of 2.77 and cash and equivalents amounting to CNY 158.34 million. However, the company's valuation is significantly below book value, as reflected in a price-to-book ratio of 0.34.
Profitability metrics show a challenging performance, with a negative return on equity of -23.13% and a negative return on assets of -16.18%. These figures indicate that the company is not generating returns that meet the cost of equity or assets, which is below the typical expectations for the medical equipment and supplies industry.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher operational and market risks if the segment faces challenges.
The company's growth trajectory is uncertain, with a net loss of CNY 407.69 million in the latest reporting period. Analysts have issued a mean recommendation of 2.00, indicating a neutral stance, with only one "buy" rating and no "strong buy" or "sell" ratings. This suggests a cautious outlook among analysts.
Risk factors include the company's negative operating and net income, which may affect its ability to sustain operations without external financing. The risk assessment indicates low dilution potential, with no immediate filing-based liquidity or dilution flags detected. However, the company's negative earnings may necessitate future capital raising, which could lead to share dilution.
Recent events include the publication of the latest financial results, which show a significant net loss and negative operating income. No recent filings or transcripts have been identified that provide additional context or strategic direction for the company.
- The company has a strong liquidity position with a current ratio of 2.77 and significant cash reserves.
- The company is not generating positive returns on equity or assets, indicating poor profitability.
- The company's revenue is concentrated in a single segment, increasing its exposure to market and operational risks.
- Analysts have a neutral stance on the company, with only one "buy" rating and no "strong buy" or "sell" ratings.
- The company's negative earnings may necessitate future capital raising, which could lead to share dilution.
- **margin_outlook_rationale**: The company's negative operating income suggests a deteriorating margin outlook driven by high costs or declining revenues.
- **rd_outlook_rationale**: No specific R&D outlook is available, but the company's negative earnings may limit investment in innovation.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,01 |
| Revenue | —no estimate | —no estimate | 972,0M UNKNOWN ERROR IN UNIVERSE PROCESSING |
| Operating income | —no estimate | —no estimate | -19,0M UNKNOWN ERROR IN UNIVERSE PROCESSING |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 2500.HK Market data — financials · 2026-05-26
- Venus Medtech (Hangzhou) Inc Market data — analyst estimates · 2026-05-26